✦ LIBER ✦

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b

✍ Scribed by Guido Antonelli; Eleonora Simeoni; Francesca Bagnato; Carlo Pozzilli; Ombretta Turriziani; Ramon Tesoro; Paola Di Marco; Claudio Gasperini; Cesare Fieschi; Ferdinando Dianzani

Book ID: 119470361
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 66 KB
Volume: 168
Category: Article
ISSN: 0022-510X
DOI: 10.1016/s0022-510x(99)00185-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

OPL098 To evaluate anti-interferon (IFN)

OPL098 To evaluate anti-interferon (IFN) neutralizing antibody (NAb) in relapsing remitting (RR) MS patients treated over the long term with an IFN beta-1b dose higher than that currently approved

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 125 KB

A case study on the effect of neutralizi

A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging

✍ A. W. Chiu; M. Ehrmantraut; N. D. Richert; V. N. Ikonomidou; S. Pellegrini; H. F 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

Impact of exposure to interferon beta-1a

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study

✍ Uitdehaag, B.; Constantinescu, C.; Cornelisse, P.; Jeffery, D.; Kappos, L.; Li, 📂 Article 📅 2011 🏛 SAGE Publications 🌐 English ⚖ 184 KB

Tolerability and safety profile of 12- t

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 µg QOD in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, parallel-group pilot study

✍ Barrie J. Hurwitz; Douglas Jeffery; Barry Arnason; Kim Bigley; Patricia Coyle; D 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 213 KB